The cancer stem-cell signaling network and resistance to therapy

Cancer Treatment Reviews

Volumn 49, Issue , 2016, Pages 25-36

  Carnero, A ^a   Garcia Mayea, Y ^b   Mir, C ^b   Lorente, J ^b   Rubio, I T ^c   LLeonart, M E ^b  

^a Instituto de Biomedicina de Sevilla   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Cancer; Conventional therapy; CSC; Metastasis; Oxidative stress; Stem cell therapy

Indexed keywords

ABC TRANSPORTER; AURANOFIN; BRONTICTUZUMAB; CD133 ANTIGEN; COLCHICINE; CYCLOPAMINE; CYCLOSPORIN A; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FOSTAMATINIB; GEMCITABINE; IDELALISIB; IPAFRICEPT; MEMBRANE RECEPTOR; METFORMIN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NAPABUCASIN; NIROGACESTAT; NIVOLUMAB; PACLITAXEL; PATIDEGIB; REPARIXIN; SONIDEGIB; TRASTUZUMAB; VANTICTUMAB; VINBLASTINE; VISMODEGIB;

AUTOPHAGY; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CHRONIC LYMPHATIC LEUKEMIA; DETOXIFICATION; EPITHELIAL MESENCHYMAL TRANSITION; GLUCOSE METABOLISM; GLYCOLYSIS; HODGKIN DISEASE; HUMAN; LEUKEMIA; LIPID PEROXIDATION; LYMPHOMA; MEDULLOBLASTOMA; MELANOMA; MEMBRANE TRANSPORT; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PANCREAS CANCER; REVIEW; SOLID TUMOR; STEM CELL SELF-RENEWAL; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; CELL DEDIFFERENTIATION; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ATP-BINDING CASSETTE TRANSPORTERS; AUTOPHAGY; CELL DEDIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LIPID PEROXIDATION; NEOPLASMS; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84978219321     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.07.001     Document Type: Review

References (100)

1. [1] Driessens, G., Beck, B., Caauwe, A., Simons, B.D., Blanpain, C., Defining the mode of tumour growth by clonal analysis. Nature 488 (2012), 527–530.
2. [2] Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988), 525–532.
3. [3] Carnero, A., Lleonart, M.E., Hypoxic microenvironment as determinant of Cancer stem cells evolution. Inside Cell, 1, 2015.
4. [4] Visvader, J.E., Lindeman, G.J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8 (2008), 755–768.
5. [5] Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006), 756–760.
6. [6] Chow, E.K., Fan, L.L., Chen, X., Bishop, J.M., Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology 56 (2012), 1331–1341.
7. [7] Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994), 645–648.
8. [8] Yiming, L., Yunshan, G., Bo, M., Yu, Z., Tao, W., Gengfang, L., et al. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis. Oncotarget 6 (2015), 42019–42027.
9. [9] Olsson, E., Honeth, G., Bendahl, P.O., Saal, L.H., Gruvberger-Saal, S., Ringner, M., et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer, 11, 2011, 418.
10. [10] Zhang, C.C., Pavlicek, A., Zhang, Q., Lira, M.E., Painter, C.L., Yan, Z., et al. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res 18 (2012), 5008–5019.
11. [11] Osipo, C., Patel, P., Rizzo, P., Clementz, A.G., Hao, L., Golde, T.E., et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27 (2008), 5019–5032.
12. [12] Sekulic, A., Migden, M.R., Oro, A.E., Dirix, L., Lewis, K.D., Hainsworth, J.D., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366 (2012), 2171–2179.
13. [13] Schatton, T., Murphy, G.F., Frank, N.Y., Yamaura, K., Waaga-Gasser, A.M., Gasser, M., et al. Identification of cells initiating human melanomas. Nature 451 (2008), 345–349.
14. [14] Wouters, J., Stas, M., Gremeaux, L., Govaere, O., Van den Broeck, A., Maes, H., et al. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS ONE, 8, 2013, e76550.
15. [15] Frank, N.Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A.M., Gasser, M., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65 (2005), 4320–4333.
16. [16] Yoon, C., Park do J, Schmidt B, Thomas NJ, Lee HJ, Kim TS, J., et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res 20 (2014), 3974–3988.
17. [17] Huang, J., Li, C., Wang, Y., Lv, H., Guo, Y., Dai, H., et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol 149 (2013), 156–168.
18. [18] Azzi, S., Gallerne, C., Romei, C., Le Coz, V., Gangemi, R., Khawam, K., et al. Human renal normal, tumoral, and cancer stem cells express membrane-bound interleukin-15 isoforms displaying different functions. Neoplasia 17 (2015), 509–517.
19. [19] Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
20. [20] Domingo-Domenech, J., Vidal, S.J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S.A., Rodriguez-Barrueco, R., et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22 (2012), 373–388.
21. [21] Gurney, A., Axelrod, F., Bond, C.J., Cain, J., Chartier, C., Donigan, L., et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 109 (2012), 11717–11722.
22. [22] Li, Y., Rogoff, H.A., Keates, S., Gao, Y., Murikipudi, S., Mikule, K., et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA 112 (2015), 1839–1844.
23. [23] L.M., A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): the Vismodegib Neoadjuvant (VISMONEO) study. J Clin Oncol, 32, 2014.
24. [24] Scott, A.L., William Jeffery Edenfield, D.J., Stephenson, Joe, Keller, Deborah, Hitron, Matthew, Li, Wei, et al. A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors. J Clin Oncol, 32, 2014, 2527.
25. [25] Derek, J., Jonker, S.A.L., Gregory, Michael Cote, Keuth, Flaherty, Fuchs, Charles S., Rashmi, Chugh, et al. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. J Clin Oncol, 33, 2015, 3615.
26. [26] Tolcher, A.W., Messersmith, W.A., Mikulski, S.M., Papadopoulos, K.P., Kwak, E.L., Gibbon, D.G., et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30 (2012), 2348–2353.
27. [27] Messersmith, W.A., Shapiro, G.I., Cleary, J.M., Jimeno, A., Dasari, A., Huang, B, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res, 2015, 60–67.
28. [28] Chu, Q., Orr, B.A., Semenkow, S., Bar, E.E., Eberhart, C.G., Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin Cancer Res 19 (2013), 3224–3233.
29. [29] Shibuya, M., Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9 (2006), 225–230 [discussion 31].
30. [30] Sahebjam, S., Bedard, P.L., Castonguay, V., Chen, Z., Reedijk, M., Liu, G., et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer 109 (2013), 943–949.
31. [31] Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
32. [32] Lee, E., Yang, J., Ku, M., Kim, N.H., Park, Y., Park, C.B., et al. Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition. Cell Death Dis, 6, 2015, e1805.
33. [33] Shibuya, K., Okada, M., Suzuki, S., Seino, M., Seino, S., Takeda, H., et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget 6 (2015), 651–661.
34. [34] Lincet, H., Icard, P., How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?. Oncogene 34 (2015), 3751–3759.
35. [35] Del Barco, S., Vazquez-Martin, A., Cufi, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., et al. Metformin: multi-faceted protection against cancer. Oncotarget 2 (2011), 896–917.
36. [36] Kondoh, H., Lleonart, M.E., Gil, J., Wang, J., Degan, P., Peters, G., et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 65 (2005), 177–185.
37. [37] Kondoh, H., Lleonart, M.E., Nakashima, Y., Yokode, M., Tanaka, M., Bernard, D., et al. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 9 (2007), 293–299.
38. [38] Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature, 2015.
39. [39] Guijarro, M.V., Leal, J.F., Blanco-Aparicio, C., Alonso, S., Fominaya, J., Lleonart, M., et al. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis 28 (2007), 2096–2104.
40. [40] Munoz-Galvan, S., Gutierrez, G., Perez, M., Carnero, A., MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFkappaB activation in breast cancer. Mol Cancer Ther 14 (2015), 1454–1465.
41. [41] Artero-Castro, A., Perez-Alea, M., Feliciano, A., Leal, J.A., Genestar, M., Castellvi, J., et al. Disruption of the ribosomal P complex leads to stress-induced autophagy. Autophagy 11 (2015), 1499–1519.
42. [42] Ramanathan, B., Jan, K.Y., Chen, C.H., Hour, T.C., Yu, H.J., Pu, Y.S., Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65 (2005), 8455–8460.
43. [43] Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458 (2009), 780–783.
44. [44] Kim, H.M., Haraguchi, N., Ishii, H., Ohkuma, M., Okano, M., Mimori, K., et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol 19:Suppl 3 (2012), S539–S548.
45. [45] Uchida, K., Szweda, L.I., Chae, H.Z., Stadtman, E.R., Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci USA 90 (1993), 8742–8746.
46. [46] Friedman, H.S., Colvin, O.M., Kaufmann, S.H., Ludeman, S.M., Bullock, N., Bigner, D.D., et al. Cyclophosphamide resistance in medulloblastoma. Cancer Res 52 (1992), 5373–5378.
47. [47] Wei, H., Wei, S., Gan, B., Peng, X., Zou, W., Guan, J.L., Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev 25 (2011), 1510–1527.
48. [48] Choi, D.S., Blanco, E., Kim, Y.S., Rodriguez, A.A., Zhao, H., Huang, T.H., et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells 32 (2014), 2309–2323.
49. [49] Espina, V., Liotta, L.A., What is the malignant nature of human ductal carcinoma in situ?. Nat Rev Cancer 11 (2011), 68–75.
50. [50] Yang, H.Z., Ma, Y., Zhou, Y., Xu, L.M., Chen, X.J., Ding, W.B., et al. Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. Cancer Lett 361 (2015), 128–136.
51. [51] Petherick, K.J., Williams, A.C., Lane, J.D., Ordonez-Moran, P., Huelsken, J., Collard, T.J., et al. Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J 32 (2013), 1903–1916.
52. [52] Wang, Y., Han, C., Lu, L., Magliato, S., Wu, T., Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology 58 (2013), 995–1010.
53. [53] Martin, V., Sanchez-Sanchez, A.M., Puente-Moncada, N., Gomez-Lobo, M., Alvarez-Vega, M.A., Antolin, I., et al. Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. J Pineal Res 57 (2014), 308–316.
54. [54] Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 72 (2012), 2768–2779.
55. [55] Bhuvanalakshmi, G., Arfuso, F., Millward, M., Dharmarajan, A., Warrier, S., Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties. PLoS ONE, 10, 2015, e0127517.
56. [56] Ding, Y., Shen, J., Zhang, G., Chen, X., Wu, J., Chen, W., CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer. Oncotarget 6 (2015), 38901–38911.
57. [57] Wang, Z., Sun, J., Feng, Y., Tian, X., Wang, B., Zhou, Y., Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. Tumour Biol, 2016.
58. [58] Chen, S.S., Chang, B.Y., Chang, S., Tong, T., Ham, S., Sherry, B., et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30 (2016), 833–843.
59. [59] Boyle, S.T., Ingman, W.V., Poltavets, V., Faulkner, J.W., Whitfield, R.J., McColl, S.R., et al. The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells. Oncogene 35 (2016), 105–115.
60. [60] Bernard, S., Danglade, D., Gardano, L., Laguillier, C., Lazarian, G., Roger, C., et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer 136 (2015), 2761–2774.
61. [61] Burke, R.T., Meadows, S., Loriaux, M.M., Currie, K.S., Mitchell, S.A., Maciejewski, P., et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget 5 (2014), 908–915.
62. [62] Bennewith, K.L., Durand, R.E., Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64 (2004), 6183–6189.
63. [63] Cheah, M.T., Chen, J.Y., Sahoo, D., Contreras-Trujillo, H., Volkmer, A.K., Scheeren, F.A., et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci USA 112 (2015), 4725–4730.
64. [64] Volonte, A., Di Tomaso, T., Spinelli, M., Todaro, M., Sanvito, F., Albarello, L., et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol 192 (2014), 523–532.
65. [65] Ginestier, C., Liu, S., Diebel, M.E., Korkaya, H., Luo, M., Brown, M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Investig 120 (2010), 485–497.
66. [66] Pietra, G., Manzini, C., Vitale, M., Balsamo, M., Ognio, E., Boitano, M., et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21 (2009), 793–801.
67. [67] Gaffen, S.L., Liu, K.D., Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004), 109–123.
68. [68] Klebanoff, C.A., Gattinoni, L., Restifo, N.P., Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J Immunother 35 (2012), 651–660.
69. [69] Byrne, K.T., Vonderheide, R.H., CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep 15 (2016), 2719–2732.
70. [70] Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S., Shu, W., Shi, H., et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520 (2015), 368–372.
71. [71] Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 28 (2010), 275–280.
72. [72] Li, X., Lewis, M.T., Huang, J., Gutierrez, C., Osborne, C.K., Wu, M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100 (2008), 672–679.
73. [73] Liu, Y., Lu, W.L., Guo, J., Du, J., Li, T., Wu, J.W., et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Controlled Release 129 (2008), 18–25.
74. [74] Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138 (2009), 645–659.
75. [75] Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N., Struhl, K., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69 (2009), 7507–7511.
76. [76] Tazzari, P.L., Tabellini, G., Ricci, F., Papa, V., Bortul, R., Chiarini, F., et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 68 (2008), 9394–9403.
77. [77] Piggott, L., Omidvar, N., Marti Perez, S., Eberl, M., Clarkson, R.W., Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res, 13, 2011, R88.
78. [78] Lau, W.M., Teng, E., Chong, H.S., Lopez, K.A., Tay, A.Y., Salto-Tellez, M., et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res 74 (2014), 2630–2641.
79. [79] Yao, H.J., Zhang, Y.G., Sun, L., Liu, Y., The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials 35 (2014), 9208–9223.
80. [80] Liu, Q., Li, R.T., Qian, H.Q., Wei, J., Xie, L., Shen, J., et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 34 (2013), 7191–7203.
81. [81] Lyakhovich, A., Michlmayr, A., Bakulina, A., Gerner, C., Oehler, R., Gasche, C., Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities. Med Chem 7 (2011), 92–98.
82. [82] Kantara, C., O'Connell, M.R., Luthra, G., Gajjar, A., Sarkar, S., Ullrich, R.L., et al. Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis. Lab Invest 95 (2015), 100–112.
83. [83] Diaz-Padilla, I., Wilson, M.K., Clarke, B.A., Hirte, H.W., Welch, S.A., Mackay, H.J., et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol 137 (2015), 216–222.
84. [84] Lee, S.M., Moon, J., Redman, B.G., Chidiac, T., Flaherty, L.E., Zha, Y., et al. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121 (2015), 432–440.
85. [85] Richter, S., Bedard, P.L., Chen, E.X., Clarke, B.A., Tran, B., Hotte, S.J., et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs 32 (2014), 243–249.
86. [86] Papayannidis, C., DeAngelo, D.J., Stock, W., Huang, B., Shaik, M.N., Cesari, R., et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J, 5, 2015, e350.
87. [87] Knoechel, B., Bhatt, A., Pan, L., Pedamallu, C.S., Severson, E., Gutierrez, A., et al. Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the gamma-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud, 1, 2015, a000539.
88. [88] Gavai, A.V., Quesnelle, C., Norris, D., Han, W.C., Gill, P., Shan, W., et al. Discovery of clinical candidate BMS-906024: a potent pan-notch inhibitor for the treatment of leukemia and solid tumors. ACS Med Chem Lett 6 (2015), 523–527.
89. [89] Robinson, G.W., Orr, B.A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol 33 (2015), 2646–2654.
90. [90] LoRusso, P.M., Rudin, C.M., Reddy, J.C., Tibes, R., Weiss, G.J., Borad, M.J., et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17 (2011), 2502–2511.
91. [91] Le, P.N., McDermott, J.D., Jimeno, A., Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 146 (2015), 1–11.
92. [92] Visus, C., Wang, Y., Lozano-Leon, A., Ferris, R.L., Silver, S., Szczepanski, M.J., et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin Cancer Res 17 (2011), 6174–6184.
93. [93] Yang, D.R., Ding, X.F., Luo, J., Shan, Y.X., Wang, R., Lin, S.J., et al. Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer. J Biol Chem 288 (2013), 16476–16483.
94. [94] Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P.L., Melotti, A., et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182 (2009), 3530–3539.
95. [95] Kim, S.Y., Kang, J.W., Song, X., Kim, B.K., Yoo, Y.D., Kwon, Y.T., et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 25 (2013), 961–969.
96. [96] Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
97. [97] Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., Dick, J.E., Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 (2006), 1167–1174.
98. [98] Ithimakin, S., Day, K.C., Malik, F., Zen, Q., Dawsey, S.J., Bersano-Begey, T.F., et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73 (2013), 1635–1646.
99. [99] Nicol, A.J., Tokuyama, H., Mattarollo, S.R., Hagi, T., Suzuki, K., Yokokawa, K., et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105 (2011), 778–786.
100. [100] Bonnet, D., Warren, E.H., Greenberg, P.D., Dick, J.E., Riddell, S.R., CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 96 (1999), 8639–8644.